#USA #Illumina #Foster City #Proteomics #Signios Bio

Groundbreaking Advancements in Proteomics Research

Signios Biosciences, a leading figure in biotechnology renowned for its commitment to science-driven approaches, has recently announced the recipients of the Illumina-Signios Bio Proteomics Grant Program. This initiative, a collaboration with Illumina, aims to significantly advance the field of proteogenomic research by providing researchers access to cutting-edge technology. The Illumina Protein Prep 9.5K™ platform, recognized as the largest next-generation sequencing (NGS) proteomics panel available, is pivotal to this program.

Following a rigorous evaluation process, Dr. Towfique Raj from the Icahn School of Medicine at Mount Sinai and Dr. Tobias V. Lanz of Stanford Medicine have been awarded grants based on their innovative research proposals. Both scientists will leverage the Illumina Protein Prep 9.5K™ platform to carry out extensive proteomic analyses that could pave the way for new discoveries in their respective fields.

Research Focus Areas

Dr. Raj's project, titled “Proteogenomic Approaches to Study GBA1-Associated Parkinson's Disease,” seeks to integrate plasma proteomics with multi-omics methodologies. His initiative aims to uncover novel biomarkers and therapeutic targets for GBA1-linked Parkinson's disease, a condition characterized by complex molecular mechanisms. By exploring these connections, Dr. Raj hopes to enhance understanding and potentially facilitate the development of personalized therapies tailored to individual patient needs.

On the other hand, Dr. Lanz’s research, titled “Combining High-Throughput Antibody Screening with Next-Generation Protein Profiling to Identify Serum Biomarkers in Patients with Neuroinflammatory Diseases,” proposes leveraging the capabilities of Illumina's 9.5K protein technology. His study focuses on identifying novel serum biomarkers related to conditions such as multiple sclerosis, neuromyelitis optica, and MOG antibody disease. His goal is to refine diagnosis procedures and improve disease stratification, thereby enhancing comprehension of the underlying mechanisms that drive neuroinflammatory diseases.

The Technology Behind the Grants

The Illumina Protein Prep 9.5K™, recognized for its SOMAmer® technology, is capable of providing a comprehensive profile of proteins present in serum and plasma by selectively binding to approximately 9,500 unique targets. Quantification takes place on the advanced NovaSeq™ sequencing system, promoting high throughput and accuracy in the results gathered. By facilitating access to such a powerful tool, the Proteomics Grant Program embodies a commitment to groundbreaking discoveries in biomedical research.

This collaboration between Signios Bio and Illumina exemplifies a shared dedication to foster innovation within the proteogenomics landscape through a data-driven scientific approach.

About the Organizations

Signios Biosciences is a dynamically evolving multiomics and bioinformatics company, underpinned by a commitment to unveil the intricate signals hidden within biological data. With the integration of state-of-the-art AI and multiomics technologies, Signios Bio is at the forefront of developing therapies and diagnostics that promise to be more effective and inclusive.

Illumina, renowned for its groundbreaking work in genomic sequencing, is dedicated to enhancing human health by unlocking the potential within the genome. As a pioneer in DNA sequencing and array-based technologies, Illumina's innovations have applications spanning life sciences, oncology, reproductive health, agriculture, and numerous emerging sectors.

Conclusion

Through the Illumina-Signios Bio Proteomics Grant Program, the future of proteomics research is bright, with the potential for significant advances in understanding complex health conditions. The awarded projects promise to aid in the creation of novel therapies, ultimately benefiting those affected by conditions like Parkinson's disease and other neuroinflammatory disorders.

This partnership marks a significant step forward in the realm of biomedical research, driven by the power of collaboration and the quest for scientific knowledge.